• Revenue up $6.5m (pcp) with growth across Europe and ANZ regions
• Gross margin improved driven by favourable customer & product mix and general manufacturing performance
• NPAT result $4.2m (1H FY25 $2.4m)

Clover Corporation Ltd reported strong financial results for the first half of FY26. Revenue increased by $6.5 million compared to the prior corresponding period (pcp), driven by growth across Europe and ANZ regions. Gross margin improved, up 850 basis points (pcp), due to favourable customer and product mix, as well as general manufacturing performance. NPAT increased to $4.2 million, up $1.8 million (pcp). The company's operational highlights include sustained customer collaboration and product qualification, leading to a more diversified portfolio and stronger margins. Growth in categories like senior nutrition and powdered drinks are providing opportunities for diversification. The company continues to appoint distributors across all regions, improving market access. The Ecuador facility and Melody Dairies in New Zealand are delivering operational benefits. The company's CholineXcel product is progressing, with packaging formats being tested and customer trials underway. Clover's DHA and ARA products are seeing growth, supported by product diversification and customer/distributor expansion. The Premneo clinical trial in India is planned, and regulatory progress is being made for other markets.

Revenue guidance for FY26 $92 to $96m

The Board anticipates that the positive momentum from the first half of FY26 will carry forward, resulting in a stronger second half, based on current demand forecasts. This outlook assumes that geopolitical tensions will not worsen and supply chains will remain stable, ensuring both inbound material supplies and outbound shipments are not disrupted throughout the rest of the financial year.